Inmune Bio, Inc. — Director's Dealing 2021

Jun 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2021-06-22

Reporting Person: Moss David J (CFO, Treasurer & Secretary, 10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-22	Option	$17.49	A	70663	Acquired	2031-06-21	Common Stock (70663)	Direct

Footnotes

F1: Each Option represents a right to receive one share of common stock of INmune Bio, Inc.

F2: Options granted pursuant to 2021 Stock Incentive Plan. Twenty-five percent of the Option will vest 12 months from the date of grant and thereafter the remaining unvested Option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the Option is 100% vested which shall occur on the four-year anniversary of the date of grant.